BMO Capital Markets Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock (NASDAQ:SRRK) had its price target raised by research analysts at BMO Capital Markets from $50.00 to $70.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. BMO Capital Markets’ price objective suggests a potential upside of 51.68% from the company’s current price.

SRRK has been the topic of a number of other reports. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday. Barclays lifted their price objective on Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday. Truist Financial increased their target price on Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Scholar Rock presently has a consensus rating of “Buy” and an average target price of $54.14.

Scholar Rock Price Performance

SRRK opened at $46.15 on Wednesday. Scholar Rock has a 12-month low of $22.71 and a 12-month high of $49.82. The company has a market cap of $5.30 billion, a price-to-earnings ratio of -13.45 and a beta of 0.70. The company has a current ratio of 6.95, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The stock has a fifty day simple moving average of $45.33 and a two-hundred day simple moving average of $39.19.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same quarter in the prior year, the business earned ($0.64) earnings per share. Research analysts predict that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Scholar Rock news, insider Mo Qatanani sold 8,484 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $47.07, for a total value of $399,341.88. Following the completion of the transaction, the insider owned 98,445 shares of the company’s stock, valued at approximately $4,633,806.15. The trade was a 7.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Junlin Ho sold 9,580 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $445,757.40. Following the transaction, the general counsel directly owned 241,545 shares of the company’s stock, valued at $11,239,088.85. The trade was a 3.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 208,470 shares of company stock valued at $9,201,778 over the last quarter. Corporate insiders own 13.30% of the company’s stock.

Institutional Trading of Scholar Rock

Several large investors have recently modified their holdings of SRRK. IFP Advisors Inc lifted its holdings in Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after acquiring an additional 450 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Scholar Rock during the 4th quarter valued at about $30,000. Summit Securities Group LLC bought a new position in shares of Scholar Rock in the 4th quarter worth approximately $31,000. Ramirez Asset Management Inc. purchased a new position in shares of Scholar Rock in the third quarter worth approximately $37,000. Finally, EverSource Wealth Advisors LLC grew its position in Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares during the period. Institutional investors own 91.08% of the company’s stock.

Key Stories Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Major analysts raised ratings and targets — BMO bumped its target to $70 (Outperform), Citigroup raised its target to $58 (Buy) and Piper Sandler lifted its target to $58 (Overweight), signaling fresh upside expectations. Analyst Price Target Raises Piper Sandler Note
• Positive Sentiment: HC Wainwright raised its FY2030 EPS forecast to $1.26 (from $1.07) and reiterated a Buy rating with a $58 price target — a bullish long‑term earnings view that contrasts with current street estimates. HC Wainwright Upgrade
• Positive Sentiment: Scholar Rock reported progress on apitegromab: management outlined a 2026 BLA resubmission plan and commercial launch preparations following favorable interactions with the FDA — this is the primary operational catalyst for upside if approval and launch proceed. FDA / BLA Progress
• Neutral Sentiment: Q4 2025 results marginally beat expectations (EPS about -$0.88 vs. consensus ~ -$0.8825), showing stability but not a strong inflection in near‑term profitability. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Street consensus still expects a negative EPS for the current fiscal year (≈ -$2.42), underlining that near‑term earnings and cash‑flow risk remain until apitegromab is approved and commercialized. Consensus EPS Context

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).